Amna Khan, MD
Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1356531024
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Pharmacosmos Therapeutics Inc. accounts for 99.4% of it on its own, with 6 other manufacturers making up the rest.
Across 39 payments — averaging $1007.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacosmos Therapeutics Inc.$39K
- Kyowa Kirin, Inc.$111
- Lilly USA, LLC$38
- Eisai Inc.$35
- Electromed, Inc.$28
- Vapotherm Inc$22
- plus $17 from 1 others
Across 4 payments — averaging $1018.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$4K
What the payments were for
- Speaking & faculty fees$18,95048%
- Travel & lodging$18,84048%
- Food & beverage$1,4954%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacosmos Therapeutics Inc. | 32 | $39,034 |
| Kyowa Kirin, Inc. | 1 | $111 |
| Lilly USA, LLC | 2 | $38 |
| Eisai Inc. | 1 | $35 |
| Electromed, Inc. | 1 | $28 |
| Vapotherm Inc | 1 | $22 |
| Genentech USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monoferric$38,599
How this compares
$39,285 in reported general payments places this provider in the 85th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TymlosAbaloparatide | 13 | $30,663 |
| SynthroidLevothyroxine Sodium | 26 | $2,738 |
| Calcitriol | 54 | $1,455 |
| Testosterone | 20 | $1,439 |
| Levothyroxine Sodium | 96 | $1,283 |
| Hydrocortisone | 13 | $558 |
| Alendronate Sodium | 48 | $468 |
| Methimazole | 17 | $220 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Philadelphia
- Serge JabbourPhiladelphia$1.2M
- Jane MayrinPhiladelphia$628K
- Intekhab AhmedPhiladelphia$528K
- Mitchell LazarPhiladelphia$358K
- Michael RickelsPhiladelphia$65K
- Janna PraterPhiladelphia$22K
- Anne CappolaPhiladelphia$17K
- Anastassia AmaroPhiladelphia$16K
- Monika ShirodkarPhiladelphia$15K
- Vijay BahlPittsburgh$998K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.